(Updated)
** Shire shares slammed after AbbVie saysit is reconsidering inversion deal
** Sharpest one-day drop for Shire shares since February2002, wipes off $14 billion in its market value and takes stockback where it was when news of AbbVie deal first broke in June
** Even after drop Shire is second-best performing stock onFTSE 100 this year, still up 31 pct, slightly behind the33 pct rise for Dixons Carphone
** Company's U.S.-listed shares down 26 pct at$181.00 premarket; AbbVie shares down 4 pct at $51.95
** As M&A premium disappears attraction of healthcare sector- best performer across Europe & the U.K. this year - remains
** AstraZeneca down 3 pct and Smith & Nephew down 3.8 pct, both feeling the heat and round out the top-3losers on the FTSE on the day (RM: vikram.subhedar.thomsonreuters.com@reuters.net)